ERBB2 and breast cancer: Cancer treatment regimens containing anthracyclines and/or human epidermal growth factor-2 (HER2) targeted therapies have significant cardiotoxic potential, therefore, patients with breast cancer are particularly vulnerable to adverse cardiac outcomes (2).